Determination of Risk Factors for Infectious Diarrhea in Patients with Hematological Malignancy.

IF 2.8 Q2 INFECTIOUS DISEASES Infection and Chemotherapy Pub Date : 2024-06-01 Epub Date: 2024-01-18 DOI:10.3947/ic.2023.0102
Şükran Şahinkaya, Zeynep Ture, Ali Unal, Gamze Kalın Ünüvar, Ayşegül Ulu Kılıç
{"title":"Determination of Risk Factors for Infectious Diarrhea in Patients with Hematological Malignancy.","authors":"Şükran Şahinkaya, Zeynep Ture, Ali Unal, Gamze Kalın Ünüvar, Ayşegül Ulu Kılıç","doi":"10.3947/ic.2023.0102","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine the risk factors of infectious diarrhea in patients undergoing chemotherapy or hematopoietic stem cell transplantation for hematological malignancies.</p><p><strong>Materials and methods: </strong>This was a prospective, observational study. Patients in whom the infectious agent was determined by laboratory examination were considered to have infectious diarrhea. Patients with diarrhea were categorized as infectious or unidentified and compared in terms of demographic data, treatments, risk factors, laboratory findings, and prognosis.</p><p><strong>Results: </strong>A total of 838 patients were hospitalized, among which 105 patients who met the inclusion criteria were included (12.5%). The patients were divided into two groups: 67 (63.8%) with unidentified diarrhea and 38 (36.2%) with infectious diarrhea. There were no differences between these groups in terms of age, sex, types of hematological malignancies, and presence of comorbidities. The most commonly isolated microorganism was <i>Clostridioides difficile</i> (12.4%). The rate of corticosteroid use was higher in the group with infectious diarrhea (39.5%) than in the group with unidentified diarrhea (7.5%) (<i>P</i> <0.001). The rate of granulocyte colony-stimulating factor (GCSF) use was higher in patients with unidentified diarrhea than in patients with infectious diarrhea (67.2% <i>vs.</i> 42.1%, <i>P</i>=0.022). The median duration of diarrhea was 9 (4-10) days in the group with infectious diarrhea and 5 (3-8) days in the group with unidentified diarrhea (<i>P</i>=0.012). According to the multivariate logistic regression model, corticosteroid treatment increased the risk of infectious diarrhea by a 4.75-fold (95% confidence interval [CI], 1.32-17.02) times. Moreover, the duration of diarrhea may result in a 1.15 (95% CI, 1.02-1.31) fold increase in the risk of infectious diarrhea, while GCSF treatment had a 2.84 (1/0.35) (95% CI, 0.12-0.96) fold risk-reducing effect against infectious diarrhea.</p><p><strong>Conclusion: </strong>Infectious diarrhea lasts longer than unidentified diarrhea in patients with hematological malignancies. Although corticosteroid use is a risk factor for developing infectious diarrhea, GCSF use has a protective effect.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"239-246"},"PeriodicalIF":2.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11224029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2023.0102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aimed to determine the risk factors of infectious diarrhea in patients undergoing chemotherapy or hematopoietic stem cell transplantation for hematological malignancies.

Materials and methods: This was a prospective, observational study. Patients in whom the infectious agent was determined by laboratory examination were considered to have infectious diarrhea. Patients with diarrhea were categorized as infectious or unidentified and compared in terms of demographic data, treatments, risk factors, laboratory findings, and prognosis.

Results: A total of 838 patients were hospitalized, among which 105 patients who met the inclusion criteria were included (12.5%). The patients were divided into two groups: 67 (63.8%) with unidentified diarrhea and 38 (36.2%) with infectious diarrhea. There were no differences between these groups in terms of age, sex, types of hematological malignancies, and presence of comorbidities. The most commonly isolated microorganism was Clostridioides difficile (12.4%). The rate of corticosteroid use was higher in the group with infectious diarrhea (39.5%) than in the group with unidentified diarrhea (7.5%) (P <0.001). The rate of granulocyte colony-stimulating factor (GCSF) use was higher in patients with unidentified diarrhea than in patients with infectious diarrhea (67.2% vs. 42.1%, P=0.022). The median duration of diarrhea was 9 (4-10) days in the group with infectious diarrhea and 5 (3-8) days in the group with unidentified diarrhea (P=0.012). According to the multivariate logistic regression model, corticosteroid treatment increased the risk of infectious diarrhea by a 4.75-fold (95% confidence interval [CI], 1.32-17.02) times. Moreover, the duration of diarrhea may result in a 1.15 (95% CI, 1.02-1.31) fold increase in the risk of infectious diarrhea, while GCSF treatment had a 2.84 (1/0.35) (95% CI, 0.12-0.96) fold risk-reducing effect against infectious diarrhea.

Conclusion: Infectious diarrhea lasts longer than unidentified diarrhea in patients with hematological malignancies. Although corticosteroid use is a risk factor for developing infectious diarrhea, GCSF use has a protective effect.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
确定血液恶性肿瘤患者感染性腹泻的风险因素。
背景:该研究旨在确定因血液恶性肿瘤接受化疗或造血干细胞移植的患者感染性腹泻的风险因素:本研究旨在确定因血液恶性肿瘤接受化疗或造血干细胞移植的患者感染性腹泻的风险因素:本研究为前瞻性观察研究。经实验室检查确定为感染性病原体的患者被定义为感染性腹泻。将腹泻患者分为感染性腹泻和不明原因腹泻,并就人口统计学数据、治疗方法、风险因素、实验室检查结果和预后进行比较:研究中,共有 838 名住院患者,其中 105 人(12.5%)符合定义标准。患者分为两组:67 例(63.8%)不明原因腹泻和 38 例(36.2%)感染性腹泻。这两组患者在年龄、性别、血液恶性肿瘤类型和是否存在合并症方面没有差异。分离微生物中比例最高的是艰难梭菌(12.4%)。感染性腹泻组使用皮质类固醇的比例(39.5%)高于不明原因腹泻组(7.5%)(P vs. 42.1%,P = 0.022)。感染性腹泻组的中位腹泻持续时间为 9(4 - 10)天,而不明原因腹泻组为 5(3 - 8)天(P = 0.012)。根据多变量逻辑回归模型,皮质类固醇治疗增加了感染性腹泻的风险,几率比[OR] = 4.75(置信区间[CI]:1.32 - 17.02)倍。结论:腹泻持续时间可能导致感染性腹泻的风险增加 1.15 倍(CI:1.02 - 1.31),而 GCSF 治疗的 OR = 2.84 倍(CI:0.12 - 0.96)可降低感染性腹泻的风险:结论:血液恶性肿瘤患者感染性腹泻持续时间较长。结论:血液恶性肿瘤患者感染性腹泻持续时间较长,使用皮质类固醇是感染性腹泻的风险因素,而使用 GCSF 则具有保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Infection and Chemotherapy
Infection and Chemotherapy INFECTIOUS DISEASES-
CiteScore
6.60
自引率
11.90%
发文量
71
审稿时长
22 weeks
期刊最新文献
Quinolone Use during the First Trimester of Pregnancy and the Risk of Atopic Dermatitis, Asthma, and Allergies of Offspring during 2011 to 2020. Use of a Real-Time Locating System in Infection Control. Clinical and Microbiological Characteristics of ST72 Methicillin-Susceptible Staphylococcus aureus: Comparison with ST72 Methicillin-Resistant S. aureus. Clinical Outcomes of Solid Organ Transplant Recipients Hospitalized with COVID-19: A Propensity Score-Matched Cohort Study. Addressing Campylobacter AMR Transmission in India: Urgent Policy Call.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1